March 15, 2019
Unison Capital, Inc.
Notice of Agreement to Transfer Shares of AYUMI Pharmaceutical Corporation
We are pleased to announce that Unison Capital Partners III, L.P. and other funds (“Unison”), for which we serve as advisors, and private equity funds managed by Blackstone (NYSE: BX) have entered into a share transfer agreement (the "Agreement") with respect to the transfer of all outstanding shares of AYUMI Pharmaceutical Corporation (“AYUMI”).
AYUMI was established as a specialty pharmaceutical company focused on rheumatoid arthritis and orthopedics through the succession of Santen Pharmaceutical Co., Ltd.’s anti-rheumatic drug business in August 2015 and SHOWA YAKUHIN KAKO CO., LTD. (“Showa”)’s medical business in December 2015. Since its initial investment in Showa in June 2012, Unison has continued to support AYUMI’s strong growth to date.
We are confident that AYUMI will further expand and advance its business in its next phase of growth under the support of its new shareholder.
The share transfer pursuant to the Agreement is planned for April 26, 2019, subject to regulatory approvals and satisfaction of customary closing conditions.
Please direct all inquiries concerning this matter to: